secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2026-07-30T20:09:36+00:00
Accession:  0001193125-26-326119
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics Q2 2026 revenue $85.4M, GAAP loss $1.05/share, revises FY revenue guidance to $330-340M
--------------------------------------------------------------------------------

- Revenue of $85.4M, up 20.1% sequentially; GAAP gross margin 30.1%.
- GAAP net loss $29.5M ($1.05 loss per share); non-GAAP loss $16.2M ($0.58 loss per share).
- Repurchased 1.5M shares for $23.8M in Q2 2026.
- Cash and investments $551.5M plus anticipated tax refund of ~$106.1M.
- Revised annual revenue guidance to $330-340M from prior range (not disclosed).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/0001193125-26-326119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/flgt-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-326119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer